Your session is about to expire
← Back to Search
Not Applicable
Calypso Knee System for Osteoarthritis
N/A
Waitlist Available
Led By David Flanigan, MD
Research Sponsored by Moximed
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants age 25 to 65 years
Be older than 18 years old
Must not have
Symptoms of osteoarthritis in the other knee or in lateral (outer) or patellofemoral compartments of the target knee
Other bone or joint conditions such as Rheumatoid arthritis, Paget's disease, Charcot's disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to 24 months
Awards & highlights
No Placebo-Only Group
Summary
This trial evaluates the safety and effectiveness of the Calypso Knee System, a device for knee pain relief, in adults aged 25-65 with medial knee osteoarthritis. The device supports the damaged area of the knee to reduce pain and improve function.
Who is the study for?
This trial is for people aged 25-65 with persistent knee pain due to osteoarthritis on the inner side, despite non-surgical treatments for at least 6 months. Participants should have a BMI of less than 35 and weigh under 300 lbs. Those with unstable knee ligaments, other joint diseases, metal allergies, infections, certain neurological conditions or taking steroids/chemotherapy are excluded.
What is being tested?
The Calypso Knee System study tests an implantable shock absorber's safety and effectiveness in individuals with symptomatic osteoarthritis in the medial compartment of their knee.
What are the potential side effects?
While specific side effects aren't listed here, typical risks may include discomfort at the implant site, potential allergic reactions to materials used in the device, infection risk post-surgery and possible impact on mobility if complications arise.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 25 and 65 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have osteoarthritis symptoms in my other knee or in parts of my target knee.
Select...
I have a condition like Rheumatoid arthritis, Paget's disease, or Charcot's disease.
Select...
My knee is unstable due to a ligament or meniscal issue.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline to 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Composite Clinical Success (CCS)
Secondary study objectives
Time to Full Weight Bearing (Days)
WOMAC Function Percent Change to Month 24
WOMAC Function Percent Change to Month 3
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CalypsoExperimental Treatment1 Intervention
Calypso Knee System
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for osteoarthritis (OA) include nonsteroidal anti-inflammatory drugs (NSAIDs), which reduce inflammation and pain by inhibiting cyclooxygenase enzymes; duloxetine, an antidepressant that helps manage chronic pain by modulating neurotransmitters; and intraarticular glucocorticoid injections, which provide short-term pain relief by reducing local inflammation. Structural support and alignment systems, such as the Calypso Knee System, aim to alleviate symptoms by redistributing load and improving joint alignment, thereby reducing stress on the affected areas.
This is particularly important for OA patients as it can help preserve joint function, delay the progression of the disease, and improve overall quality of life.
Knee osteoarthritis: pathophysiology and current treatment modalities.
Knee osteoarthritis: pathophysiology and current treatment modalities.
Find a Location
Who is running the clinical trial?
MoximedLead Sponsor
6 Previous Clinical Trials
574 Total Patients Enrolled
5 Trials studying Osteoarthritis
251 Patients Enrolled for Osteoarthritis
David Flanigan, MDPrincipal InvestigatorThe Ohio State University Wexner Medical Center
3 Previous Clinical Trials
210 Total Patients Enrolled
2 Trials studying Osteoarthritis
201 Patients Enrolled for Osteoarthritis
Rose WeinsteinStudy DirectorMoximed
1 Previous Clinical Trials
50 Total Patients Enrolled
1 Trials studying Osteoarthritis
50 Patients Enrolled for Osteoarthritis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not on steroids or chemotherapy that could affect the study.I have inner knee pain from osteoarthritis despite 6 months of non-surgical treatment.I am between 25 and 65 years old.I have osteoarthritis symptoms in my other knee or in parts of my target knee.I do not have allergies to metals, active infections, or specific neurological conditions.I have a condition like Rheumatoid arthritis, Paget's disease, or Charcot's disease.I am between 25 and 65 years old.Your weight is less than 300 pounds and your body mass index (BMI) is less than 35.My knee is unstable due to a ligament or meniscal issue.
Research Study Groups:
This trial has the following groups:- Group 1: Calypso
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Osteoarthritis Patient Testimony for trial: Trial Name: NCT03671213 — N/A
Share this study with friends
Copy Link
Messenger